MB09, a denosumab biosimilar candidate: Biosimilarity demonstration in a phase I study in healthy subjects

Documenti analoghi

• A pharmacokinetic study comparing the biosimilar HEC14028 and Dulaglutide (Trulicity®) in healthy Chinese subjects
  di: Xianglei Gao, et al.
  Pubblicazione: (2024)
• Safety, pharmacokinetics, and food effect of sudapyridine (WX‐081), a novel anti‐tuberculosis candidate in healthy Chinese subjects
  di: Chengyin Yu, et al.
  Pubblicazione: (2024)
• Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non‐covalent BTK inhibitor, in healthy subjects: First‐in‐human phase I study
  di: Kyoko Miyamoto, et al.
  Pubblicazione: (2024)
• Safety, pharmacokinetics, and pharmacodynamics of ART‐648, a PDE4 inhibitor in healthy subjects: A randomized, placebo‐controlled phase I study
  di: Akira Tanaka, et al.
  Pubblicazione: (2024)
• Pharmacokinetic comparison of subcutaneously administered CT‐P13 (biosimilar of infliximab) via autoinjector and pre‐filled syringe in healthy participants
  di: Ye Chan Park, et al.
  Pubblicazione: (2024)